Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. - Wikidata - awgldk - TriplyDB

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

http://www.wikidata.org/entity/Q34050239

about

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review Targeted therapies in development for non-small cell lung cancer EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study.Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.The quest to overcome resistance to EGFR-targeted therapies in cancer.Inhibition of lung tumor growth in nude mice by siRNA(CD31) targeting PECAM-1.Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis.Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536 Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Carcinoma of unknown primary site treated with Carboplatin + Paclitaxel + bevacizumab + erlotinib and its maintenance chemotherapy Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis.Emerging treatment for advanced lung cancer with EGFR mutation.Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials.Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients.Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis

P2860

Q26744339-6678C5A1-5785-44F3-A0D6-740F901DDE6E Q26786618-07EE1470-B366-47A0-9802-62D6E15F5971 Q26796456-EC56AC71-EBDE-488F-A62B-9EC4CE3EEA9C Q26859993-2AE50911-C36D-4A7F-9C3C-16C1B835F3E1 Q26995204-CFDE7418-16CB-47F1-A54A-02B0C3DBAE6B Q27014117-1C15661E-D6A5-463C-BD08-F7914D3088A6 Q27022535-BA35195B-C3DC-4A69-8E90-AEFE13D3157E Q27022852-0A374DEB-65CF-4959-85A9-C9377C1312B9 Q27852543-C89E0E5C-AEC7-4854-BC4E-E66578C618A3 Q28533949-B9346820-E548-42E1-AE0E-FADEFD4AAA56 Q28534015-E77E0747-1D19-4FD8-958B-852A0A2AB878 Q30356434-A2F7A161-E2CF-4070-8119-579F96746A42 Q30588681-50EC8C57-989D-45E7-A29C-0C0E0F4FB3D5 Q31060162-9A442494-7660-4A1E-90B5-6DEACA9B0366 Q31152878-F7F425AA-244C-4E3E-8686-D4D646688F86 Q33165980-D1BD8357-612B-4DCE-B4D6-13641354F7EC Q33418555-C1656432-9A9C-4268-A780-583BAF0143DB Q33429242-4AEA02AE-1922-4C1B-8A34-89DB85C3A36E Q33599860-0EBAEB63-7FEC-4E90-9151-74067DE480F1 Q33637887-54345DF4-896E-4E48-A5D8-F40B8B7FF08E Q33662730-5A373760-EED5-4574-A14B-D869202B6F44 Q33725976-F1DEF332-F892-4C7E-8F4A-B6183A9FBBA2 Q33778468-6066A09F-77AB-4123-A3E4-75C18BFF84A5 Q33787355-F27D192B-E750-4CB9-B163-DDAEF05968F4 Q33789403-E2CB85AD-406D-40EE-A356-5FB8454C7FE3 Q33810763-F3043669-AA14-486E-B7F3-B4BE3FD15E58 Q33904867-F6BA93BA-AD0D-4610-B713-BA32D023AC2D Q34011705-EFB64709-B631-4F84-99E9-D9ECC7E3CC2E Q34250003-6370AF23-E3C9-4AF7-9053-E40062F12304 Q34259395-662170F2-A346-4C57-B187-FD462253B922 Q34390684-FFE33165-48C8-4A42-8E96-D58F1C2A6D83 Q34483953-4173AD2D-D5F8-4AD3-9D61-E237A97FE336 Q34538361-EF9C1304-3157-4E8F-953A-61730653448D Q34639843-6C628562-8058-497A-8477-4ADEB6C00AE7 Q34685531-8BB22413-E773-4B43-813E-C5B7D48E72FB Q35010777-68F741CA-CE1B-45A6-8B3C-B98E5C77F39A Q35200483-91249EB0-2748-42D4-BBDC-5838C1AA202F Q35545472-6B54BE0C-5F33-475C-B1A9-68B2DBEE74D2 Q35632548-8DA0A8CD-4F00-468E-9CB4-83BDFB0199E7 Q35649624-AFE75FE1-8194-460E-BE17-5FC2CC4B4CF6

P2860

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

http://www.wikidata.org/entity/Q34050239

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@ast

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@en

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@nl

type

label

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@ast

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@en

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@nl

prefLabel

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@ast

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@en

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@nl

P1433

Q34050239-ECEAF983-A373-4316-B33B-558697D86158

P1476

Q34050239-CFF06B0F-9CBF-441D-8EA9-B4A75C0E3E70

P2093

Q34050239-3439B4FB-807C-48B8-A157-3116405D3E03

Q34050239-36E1667D-1F21-42AC-B6E7-FDD42E7ECB46

Q34050239-546E740D-1B87-4962-88FC-FEB59D4ACEC3

Q34050239-566EC566-07B1-4D5E-898A-4492C61F243F

Q34050239-9F9B3C83-FC49-4472-9D02-7ADC5EA40DD2

Q34050239-B0815791-8A7C-40FD-9044-A67D33398A0A

Q34050239-EDFA71E0-1FAF-490F-A0BE-5A39949BB2AE

Q34050239-F25642EE-354A-44C7-B4D6-2ADFCF5D2961

P2860

Q34050239-1717C8F3-7A9F-4678-84D6-91F6D12ED3E7

Q34050239-202C7A12-4C48-41E8-A324-46204E03728E

Q34050239-2E75A4DA-CBC6-43B0-9641-BB9AB8DB2691

Q34050239-2E9B17A4-5BD2-48EF-8AA2-1F54719EC7FB

Q34050239-2F40033A-927D-4031-917F-82FD55727D58

Q34050239-42AB9459-139A-4A71-A79F-799D43305BF9

Q34050239-47BBB468-D91C-4ABA-9ED7-DC3026C5E581

Q34050239-4DC95B26-586E-4CCB-B3A1-9397E0368C6C

Q34050239-6F90C104-0BD8-4C36-9A0B-ADAD7645A422

Q34050239-87718836-D987-468E-80C0-DE5D7AF16E58

P304

Q34050239-F122C667-A87A-4C49-93ED-8509D7947D4E

P31

Q34050239-2F8B7EF2-B541-47BB-B343-CBAAAADA844E

P356

Q34050239-438A95F8-CA61-4277-9D90-51ADE6FD476A

P407

Q34050239-B3EE667C-A358-452C-B457-EB7AB6AE9255

P433

Q34050239-C64FBEDE-4607-434C-A172-C01E1539939E

P478

Q34050239-99C0BBC3-01E5-404B-B4E0-043548A521B6

P50

Q34050239-005D2327-AFCF-4780-8307-585F1022CDFC

Q34050239-39873B43-16A6-42E6-B23F-A760691D40C5

P577

Q34050239-5010790B-2840-45E8-9A38-71EA0926D848

P698

Q34050239-1D76E1FC-A760-4E47-B693-C196E2CB59FA

P921

Q34050239-189D7719-B0B9-43CA-9E64-EBAF473ECD6E

Q34050239-39D7231A-88D1-4164-979F-05D8589E55DF

Q34050239-4049A67A-FA12-47AC-8A03-582A435FD12A

Q34050239-76B4A794-6ED5-4955-953E-6BC00A9D3D37

P932

Q34050239-7E973111-90AD-4A95-B665-97226565DEBC

P356

S0140-6736(11)60545-X

P1433

P1476

Efficacy of bevacizumab plus e ...... ebo-controlled, phase 3 trial.

@en

P2093

Chang-Heok Soh

http://www.w3.org/2001/XMLSchema#string

Frederique Bustin

http://www.w3.org/2001/XMLSchema#string

Gordana Vlahovic

http://www.w3.org/2001/XMLSchema#string

Gregory A Otterson

http://www.w3.org/2001/XMLSchema#string

Lowell Hart

http://www.w3.org/2001/XMLSchema#string

Patrick Flynn

http://www.w3.org/2001/XMLSchema#string

Paula O'Connor

http://www.w3.org/2001/XMLSchema#string

Rafat Ansari

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Cancer statistics, 2010

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

The ErbB/HER receptor protein-tyrosine kinases and cancer.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

P304

1846-1854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(11)60545-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9780

http://www.w3.org/2001/XMLSchema#string

P478

377

http://www.w3.org/2001/XMLSchema#string

P50

John D Hainsworth

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21621716

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4134127

http://www.w3.org/2001/XMLSchema#string